Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages - Wikidata - wikimedia - TriplyDB

Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages

Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages

http://www.wikidata.org/entity/Q33618760

about

Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1).Circular RNA Complement Factor H (CFH) Promotes Glioma Progression by Sponging miR-149 and Regulating AKT1

P2860

Q55456919-327DE515-78EC-43B2-AD05-FA4AA1CBE88E Q58773484-7C7ADDC9-F710-4679-A285-7363F1B8ECE9

P2860

Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages

http://www.wikidata.org/entity/Q33618760

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Progression of motor deficits ...... therapy at symptomatic stages

@ast

Progression of motor deficits ...... therapy at symptomatic stages

@en

type

label

Progression of motor deficits ...... therapy at symptomatic stages

@ast

Progression of motor deficits ...... therapy at symptomatic stages

@en

prefLabel

Progression of motor deficits ...... therapy at symptomatic stages

@ast

Progression of motor deficits ...... therapy at symptomatic stages

@en

P1433

Q33618760-5DACD544-6B28-4559-80A9-867AF2F22832

P1476

Q33618760-397233AB-C829-4632-8594-D9C926F8873F

P2093

Q33618760-554ED9B1-C1C3-4FA8-861F-BCAD4F462ADE

Q33618760-5669DE8F-40C7-4003-BF6E-A21907C62FA8

Q33618760-7CA9665E-DD55-41B4-8F45-5DB26A65BF1F

Q33618760-9EFDA420-72C6-4CD8-81E8-B67A687B30F3

Q33618760-E41447A1-4A3C-4754-B927-792382768CD8

P2860

Q33618760-123E1DFD-EDFE-4610-9500-5852287DAE62

Q33618760-255C4167-1A26-4B99-97C8-6FF0601157A7

Q33618760-25651C27-4AEF-43D7-9568-E54D88193335

Q33618760-2D6E8460-C024-4464-9BC8-F5222E7772C7

Q33618760-2ECFA424-E815-4C7B-836A-AAB368EBFE6A

Q33618760-325928ED-D664-47FF-96CC-92C44DA43E56

Q33618760-3A2ACC78-1301-4653-B647-E238D1FC808D

Q33618760-3C0C39E8-C596-40E1-B78A-96F2435ED5C0

Q33618760-53AA6197-65BB-4E32-9304-9285AA718A54

Q33618760-5A597CBF-18C9-4A56-BF62-0EB157637BBE

P304

Q33618760-E5E7EC44-F740-49F2-A568-C301C5A6295C

P31

Q33618760-27346E5B-72B6-4C54-8BD7-2748342F78E1

P356

Q33618760-CF375425-98EC-4406-972B-0B651D0AFCD2

P407

Q33618760-11DBEF61-6B00-4E52-9C4B-7E910A2FF6C3

P433

Q33618760-234011D4-1075-4F89-A2D9-C42B871875AB

P478

Q33618760-778A1035-752A-4101-A34A-A62133740A11

P50

Q33618760-59977616-E9EE-4855-B8E4-8730FE3CBB8D

Q33618760-84551781-5102-4662-A27F-E4CBDE50F108

P577

Q33618760-7C9FF17C-0603-4540-BCA0-6C14908BD31E

P698

Q33618760-1392604A-9F62-4374-A642-E5BEBD79E99B

P932

Q33618760-1339D7FD-47F2-4B52-B29B-BC3D9887808C

P356

ONCOTARGET.15328

P1433

P1476

Progression of motor deficits ...... therapy at symptomatic stages

@en

P2093

Eleonora Vannini

http://www.w3.org/2001/XMLSchema#string

Federica Maltese

http://www.w3.org/2001/XMLSchema#string

Francesco Olimpico

http://www.w3.org/2001/XMLSchema#string

Laura Baroncelli

http://www.w3.org/2001/XMLSchema#string

Mario Costa

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice

Reducing GABAA-mediated inhibition improves forelimb motor function after focal cortical stroke in mice

Tests to assess motor phenotype in mice: a user's guide.

CNF1 improves astrocytic ability to support neuronal growth and differentiation in vitro.

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches

Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy.

The organization of the forelimb representation of the C57BL/6 mouse motor cortex as defined by intracortical microstimulation and cytoarchitecture

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model

P304

23539-23550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15328

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28212563

http://www.w3.org/2001/XMLSchema#string

P932

5410325

http://www.w3.org/2001/XMLSchema#string